Visual acuity after intravitreal triamcinolone for diabetic macular edema refractory to laser treatment: A meta-analysis

Canadian Journal of Ophthalmology

Volumn 44, Issue 5, 2009, Pages 587-593

  Rudnisky, Christopher J ^a,d   Lavergne, Valery ^b   Katz, David ^c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c BROWN UNIVERSITY   (United States)

^d ROYAL ALEXANDRA HOSPITAL   (Canada)

Author keywords

Diabetic retinopathy; Laser; Macular edema; Photocoagulation; Triamcinolone

Indexed keywords

TRIAMCINOLONE;

ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC PATIENT; DRUG EFFICACY; HUMAN; LASER COAGULATION; OUTCOMES RESEARCH; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 70349469716     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.3129/i09-086     Document Type: Article

References (34)

1. Ferris FL 3rd, Patz A. Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol 1984;28:452-461
2. Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group. Am J Ophthalmol 1976;81:383-396
3. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985;103:1796-1806
4. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98:766-785
5. Bresnick GH. Diabetic maculopathy. A critical review highlighting diffuse macular edema. Ophthalmology 1983;90:1301-1317
6. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology 1991;98:1594-1602
7. Lewis H, Abrams GW, Blumenkranz MS, Campo RV. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology 1992;99:753-759
8. Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 2006;113:1706-1712
9. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109:920-927 (Pubitemid 34465226)
10. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998;105:1801-1815
11. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984;102:527-532 (Pubitemid 14127839)
12. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984;102:520-526 (Pubitemid 14127838)
13. Seidell JC. Obesity, insulin resistance and diabetes - a worldwide epidemic. Br J Nutr 2000;83:S5-8.
14. Tan MH, MacLean DR. Epidemiology of diabetes mellitus in Canada. Clin Invest Med 1995;18:240-246
15. Young TK, Reading J, Elias B, O'Neil JD. Type 2 diabetes mellitus in Canada's first nations: status of an epidemic in progress. CMAJ 2000;163:561-566 (Pubitemid 30742942)
16. Grover D, Li TJ, Chong CC. Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev 2008:CD005656. (Pubitemid 351807600)
17. Lam DS, Chan CK, Mohamed S, et al. Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: six-month outcomes. Ophthalmology 2007;114:2162-2167 (Pubitemid 350181096)
18. Moher D, Cook DJ, Eastwood S, Olkin J, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999;354:1896-1900
19. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-2012
20. Thein R, Pollack A, Bukelman A, et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema - one year follow-up [in Hebrew]. Harefuah 2005;144:759-62, 824. (Pubitemid 41769282)
21. Ferris FL 3rd, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol 1982;94:91-96
22. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Xhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006;113:1533-1538 (Pubitemid 44292310)
23. Jonas JB, Kamppeter BA, Harder B, Vossmerbaeumer U, Sauder G, Spandau UH. Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. J Ocul Pharmacol Ther 2006;22:200-207 (Pubitemid 44051133)
24. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560
25. Larsson J, Kifley A, Zhu M, et al. Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial. Acta Ophthalmol 2008;87:275-280
26. Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 2004;111:218-224 (Pubitemid 38183217)
27. Rumelt S, Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Evidence-Based Ophthalmology 2005;6:92-94 (Pubitemid 40852922)
28. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008;115:1447-1449
29. Audren F, Erginay A, Haouchine B, et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial. Acta Ophthalmol Scand 2006;84:624-630 (Pubitemid 44317541)
30. Ockrim ZK, Sivaprasad S, Falk S, et al. Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. Br J Ophthalmol 2008;92:795-799 (Pubitemid 351839571)
31. Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 2004;111:2044-2049
32. Dehghan MH, Ahmadieh H, Ramezani A, Entezari M, Anisian A. A randomized, placebo-controlled clinical trial of intravitreal triamcinolone for refractory diabetic macular edema. Int Ophthalmol 2008;28:7-17. (Pubitemid 351308679)
33. Er H, Yilmaz H. Intravitreal cortisone injection for refractory diffuse diabetic macular edema. Ophthalmologica 2005;219:394-400. (Pubitemid 41628304)
34. Lang Y, Leibu R, Shoham N, Miller B, Perlman J. Evaluation of intravitreal kenalog toxicity in humans. Ophthalmology 2007;114:724-731 (Pubitemid 46483697)